The most advanced agents, METMAb, a MET neutralizing antibody and Tivantinib, a small molecule inhibitor of MET have both failed in phase III clinical trials [15]; despite this, there is considerable interest in the therapeutic potential of MET inhibition in NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.